Berberine and Lung Cancer: From Pure Form to Its Nanoformulations Publisher



Z Tamtaji ZEINAB ; E Sheikhsagha ELHAM ; M Behnam MOHAMMAD ; F Nabavizadeh FATEMEH ; M Shafiee Ardestani MEHDI ; F Rahmatidehkordi FATEMEH ; M Aschner MICHAEL ; Hr Mirzaei Hamed REZA ; Or Tamtaji Omid REZA
Source: Asia-Pacific Journal of Clinical Oncology Published:2024

Abstract

Lung cancer is the most fatal cancer worldwide. The etiology of lung cancer has yet to be fully characterized. Smoking and air pollution are several risk factors for lung cancer. Berberine, an isoquinoline alkaloid, is an antihyperglycemic, antidepressant, antioxidative, anti-inflammatory, and anticancer compound. Evidence substantiates that berberine has antitumor effects, exerting its effects by targeting a variety of cellular and molecular processes, such as apoptosis, autophagy, cell cycle arrest, migration, and metastasis. Although the beneficial effects of berberine have been reported, some limitations including low bioavailability and absorption as well as poor aqueous solubility have hindered its clinical application. Nanotechnology and nanodelivery bioformulation approaches may bypass these limitations. In addition, the combination of berberine with other therapies has been shown to result in greater treatment efficacy for lung cancer. Herein, we summarize cellular and molecular pathways that are affected by berberine, its clinical efficacy upon various combinations, and the potential for nanotechnology in lung cancer therapy. © 2024 Elsevier B.V., All rights reserved.